SCTX

Scribe Therapeutics Inc. - Common Stock (SCTX)

About Scribe Therapeutics Inc. - Common Stock (SCTX)

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.

Details

Daily high

$31.45

Daily low

$28.50

Price at open

$30.21

52 Week High

$39.60

52 Week Low

$15.00

Market cap

542.8M

Dividend yield

Volume

148,197

Avg. volume

227,552

P/E ratio

Scribe Therapeutics Inc. - Common Stock News